US Stock MarketDetailed Quotes

NVO Novo-Nordisk A/S

Watchlist
  • 123.450
  • -0.450-0.36%
Close Apr 16 16:00 ET
  • 124.410
  • +0.960+0.78%
Pre 07:33 ET
550.11BMarket Cap46.58P/E (TTM)

About Novo-Nordisk A/S Company

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv?rd, Denmark.

Company Profile

SymbolNVO
Company NameNovo-Nordisk A/S
Listing DateJul 9, 1981
Founded1931
CEOMr. Lars Fruergaard Jorgensen
MarketNYSE
Employees64319
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressNovo Allé 1
CityBagsv?rd
ProvinceCapital Region
CountryDenmark
Zip Code2880
Phone45-44-44-88-88

Company Executives

  • Name
  • Position
  • Salary
  • Lars Fruergaard Jorgensen
  • Chief Executive Officer and President
  • --
  • Marcus Schindler, PhD
  • Executive Vice President, Research and Early Development and Chief Scientific Officer
  • 23.60M
  • Karsten Munk Knudsen
  • Executive Vice President and Chief Financial Officer
  • 26.40M
  • Maziar Mike Doustdar
  • Executive Vice President, International Operations
  • 2.20M
  • Henrik Ehlers Wulff
  • Executive Vice President, Product Supply, Quality Assurance, Digital Data and IT
  • 25.90M
  • Camilla Sylvest
  • Executive Vice President, Commercial Strategy and Corporate Affairs
  • 23.40M
  • Martin Holst Lange
  • Executive Vice President, Development
  • 23.40M
  • Doug Langa
  • Executive Vice President, North America Operations
  • 2.20M
  • Ludovic Helfgott
  • Executive Vice President, Rare Disease
  • 2.20M
  • Henrik Poulsen
  • Vice Chairman of the Board
  • 2.40M
  • Helge Lund
  • Chairman of the Board
  • 3.90M
  • Elisabeth Dahl Christensen
  • Director
  • 1.10M
  • Kasim Kutay
  • Director
  • 1.30M
  • Liselotte Hyveled
  • Director
  • 1.10M
  • Mette Bojer Jensen
  • Director
  • 1.30M
  • Thomas Rantzau
  • Director
  • 1.10M
  • Christina Law
  • Independent Director
  • 1.70M
  • Andreas Fibig
  • Independent Director
  • 1.40M
  • Laurence Debroux
  • Independent Director
  • 2.10M
  • Dr. Sylvie Gregoire,Pharm.D.
  • Independent Director
  • 2.00M
  • Dr. Martin W. Mackay, PhD
  • Independent Director
  • 1.80M

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg